Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine
Category: #health  By Pankaj Singh  Date: 2019-10-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine

The trial will reportedly examine the safety, tolerability and immunogenicity of MVA-BN WEV

The U.S. is currently facing the worst outbreak of the Eastern equine encephalitis virus (EEEV). Over 30 cases were reported in 2019, which included 9 fatalities, majorly in the north-eastern regions of the country, where mosquitoes have been found to carry the virus.

Denmark-based biotechnology company Bavarian Nordic recently announced the commencement of the first-in-human trial of its prophylactic vaccine candidate, MVA-BN® WEV, for the prevention of equine encephalitis virus.

Reportedly funded by the U.S. Department of Defense Joint Project Manager for Chemical, Biological, Radiation and Nuclear Medicine (JPM CBRN Medical), the project is a multi-year agreement valued at $36 million that aims to formulate a vaccine against three different forms of the equine encephalitis virus – Eastern (EEEV), Venezuelan and (VEEV)Western (WEEV). Currently, there are no preventive vaccines available for the virus.

The Phase 1 trial will evidently analyze the safety, efficacy and tolerability of MVA-BN WEV in 45 healthy adults divided into three treatment groups which will be administered with different doses of the vaccine. It is estimated that promising results from the study will be achieved and available by 2020.

Sources familiar with the matter reported that a successful Phase 1 trial, based on demonstrating favorable safety and efficacy, could lead to additional funding beyond the initial USD 36 million contract award, to promote further clinical, preclinical development and manufacturing to obtain licensure in the U.S.

Bavarian Nordic President and CEO Paul Chaplin was reported saying that following the recent FDA approval of its smallpox vaccine, which was formulated in collaboration with numerous U.S. Government agencies and has become a vital part of the national stockpile, the company looks forward to advancing the new & innovative program and help realize the U.S. government’s goal to develop a wide range of medical countermeasures to protect U.S. citizens.

The occurrence of Triple E virus has significantly increased in US, highlighting the need to develop a vaccine to tackle the disease. To address the unmet medical needs, the company will utilize the unique properties of its MVA-BN platform technology and expects to continue the effort with DOD on the critical project, Chaplin noted.  

Source Credits –http://www.bavarian-nordic.com/investor/news/news.aspx?news=5768



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...